Cargando…
Comparison between regular additional endobiliary radiofrequency ablation and photodynamic therapy in patients with advanced extrahepatic cholangiocarcinoma under systemic chemotherapy
BACKGROUND AND AIMS: Extrahepatic cholangiocarcinoma (eCCA) remains a malignancy with a dismal prognosis. The first-line standard of care includes systemic chemotherapy (SC) and biliary drainage through stenting. Endobiliary ablative techniques, such as photodynamic therapy (ePDT) and radio-frequenc...
Autores principales: | Möhring, Christian, Khan, Oliver, Zhou, Taotao, Sadeghlar, Farsaneh, Mahn, Robert, Kaczmarek, Dominik J., Dold, Leona, Toma, Marieta, Marinova, Milka, Glowka, Tim R., Matthaei, Hanno, Manekeller, Steffen, Kalff, Jörg C., Strassburg, Christian P., Weismüller, Tobias J., Gonzalez-Carmona, Maria A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10497756/ https://www.ncbi.nlm.nih.gov/pubmed/37711210 http://dx.doi.org/10.3389/fonc.2023.1227036 |
Ejemplares similares
-
Impact of regular additional endobiliary radiofrequency ablation on survival of patients with advanced extrahepatic cholangiocarcinoma under systemic chemotherapy
por: Gonzalez-Carmona, Maria A., et al.
Publicado: (2022) -
Case Report: Sustained complete remission on combination therapy with olaparib and pembrolizumab in BRCA2-mutated and PD-L1-positive metastatic cholangiocarcinoma after platinum derivate
por: Zhou, Taotao, et al.
Publicado: (2022) -
First Line and Second Line Chemotherapy in Advanced Cholangiocarcinoma and Impact of Dose Reduction of Chemotherapy: A Retrospective Analysis
por: Möhring, Christian, et al.
Publicado: (2021) -
Multimodal and systemic therapy with cabozantinib for treatment of recurrent hepatocellular carcinoma after liver transplantation: A case report with long term follow-up outcomes
por: Mahn, Robert, et al.
Publicado: (2021) -
Second-line and third-line therapy with nanoliposomal irinotecan (nal-IRI) in pancreatic cancer: a single-center experience and review of literature
por: Möhring, Christian, et al.
Publicado: (2023)